Literature DB >> 7769309

Protection of mice from group A streptococcal skin infection by interleukin-12.

D W Metzger1, R Raeder, V H Van Cleave, M D Boyle.   

Abstract

It has been shown that interleukin (IL)-12 induces cell-mediated immunity and provides significant protection against intracellular organisms. The ability of this cytokine to enhance immunity in a mouse model of group A streptococcal skin infection was studied. Outbred CD1 mice were injected for 3 consecutive days with 0.1 microgram of recombinant murine IL-12 before or after challenge with strain 64/14 group A streptococci. In both cases, in vivo IL-12 treatment significantly decreased the rate of death after infection and increased survival over the period of experimental observation. Thus, IL-12 may be useful for treatment of gram-positive bacterial infections. The time course of the experiments suggests that IL-12 is acting in this model system to enhance natural, rather than acquired, immunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769309     DOI: 10.1093/infdis/171.6.1643

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Intrathecal production of interleukin-12 and gamma interferon in patients with bacterial meningitis.

Authors:  R F Kornelisse; C E Hack; H F Savelkoul; T C van der Pouw Kraan; W C Hop; G van Mierlo; M H Suur; H J Neijens; R de Groot
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection.

Authors:  Keer Sun; Sharon L Salmon; Steven A Lotz; Dennis W Metzger
Journal:  Infect Immun       Date:  2007-01-08       Impact factor: 3.441

3.  STAT4 is required for antibacterial defense but enhances mortality during polymicrobial sepsis.

Authors:  C J Godshall; A B Lentsch; J C Peyton; M J Scott; W G Cheadle
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain.

Authors:  Nathalie S Duckett; Sofia Olmos; Douglas M Durrant; Dennis W Metzger
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

5.  Role of interleukin 12 in experimental neonatal sepsis caused by group B streptococci.

Authors:  G Mancuso; V Cusumano; F Genovese; M Gambuzza; C Beninati; G Teti
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

6.  Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis.

Authors:  B Echtenacher; M A Freudenberg; R S Jack; D N Männel
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

7.  Aberrant inflammatory response to Streptococcus pyogenes in mice lacking myeloid differentiation factor 88.

Authors:  Torsten G Loof; Oliver Goldmann; André Gessner; Heiko Herwald; Eva Medina
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  Downregulation of CD40 ligand response in monocytes from sepsis patients.

Authors:  Anna Sinistro; Cristiana Almerighi; Chiara Ciaprini; Silvia Natoli; Emanuele Sussarello; Sara Di Fino; Francesca Calò-Carducci; Giovanni Rocchi; Alberto Bergamini
Journal:  Clin Vaccine Immunol       Date:  2008-10-22

9.  Interleukin-12 and tumor necrosis factor alpha mediate innate production of gamma interferon by group B Streptococcus-treated splenocytes of severe combined immunodeficiency mice.

Authors:  C A Derrico; K J Goodrum
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

10.  Lipopolysaccharide desensitizes monocytes-macrophages to CD40 ligand stimulation.

Authors:  Anna Sinistro; Chiara Ciaprini; Silvia Natoli; Emanuele Sussarello; Francesca Calò Carducci; Cristiana Almerighi; Marcella Capozzi; Francesca Bolacchi; Giovanni Rocchi; Alberto Bergamini
Journal:  Immunology       Date:  2007-06-29       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.